utenzi

Happy St Valentine's Day everyone. I did the flower thing and for some reason they were delivered yesterday. My girlfriend didn't mind but I was a bit annoyed. Judy --what's going on with your industry? LOL I bet it is a wee bit stressful for florists this week. I sent roses to Ren and tulips to my parents. 18 of one and 20 of the other. A lot of plants lose their lives to this little celebration. As of 4pm Tuesday, I once again have heat in my house. Thank God! It's about to get cold again and I'd not want to have my heating unit on the sideline when the mercury drops below 20f again like it's supposed to later this week. The bad news is that the repair cost almost $500. To be exact, it was $498.75, and that was almost evenly split between the labor cost and the R-22 (freon) that needed to be put back into the system. More than 10 pounds worth at $22 something a pound. Hell, prime Kobe beef costs less than that! On the stock front I bought 1,000 shares of Chi...

I've been watching Onyx Pharmaceuticals for 6 months now, ever since I bought a few shares of their stock. I posted about it at that time. As you can see from that link, the stock was sharply down on some bad news and I bought my shares at the corrected price. That was due to my feeling that the stock had been unjustly punished by the market for news that didn't really hurt their core business very sharply. Today the stock is soaring on good news. To wit, a report that stated that their Nexavar cancer medicine, which they share with Bayer, helped patients with liver tumors live longer. While it is certainly good news for the company, I don't think it's good enough to warrent the stock moving up 80%--yet that's what has happened. Biotech stocks really do move irrationally. It's like watching the mood swings of a 13 year old girl. And oddly enough that's half the fun of investing in biotech stocks. Go figure. (and in case you're curious--I did sell it, I ...

Nexavar is a drug taken orally that targets both the tumor cell and the tumor vasculature. Nexavar targets members of two classes of kinases known to be involved in both cell proliferation and angiogenesis, the processes that enable cancer growth. These kinases include RAF kinase, VEGFR-1, 2, and 3, PDGFR-beta, KIT, and FLT-3. Several of those genes are ones that I find pop up when I run microarrays on my tumor samples so the action of this drug interests me. However my work is on breast cancer and Nexavar is used to combat advanced kidney cancer. But that's all beside the point--the reason for this post is that I bought a thousand shares of Onyx today. As you can see in the chart to the left, there was a huge drop in price between last Friday and today. You see, Onyx had some bad news last week. After the close of the stock market in NY it was revealed that the Phase 3 clinical trial of Nexavar in patients with advanced melanoma did not meet its primary endpoint. As a result the p...